Live from OSN New York 2023
Click Here to Manage Email Alerts
Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, chat with Peter Slack, Greg Kunst, Rich Small and Uday Devgan, MD, FACS, FRCS, live from OSN New York.
- Welcome to the Eyeluminaries podcast :01
- Review of episode 18 :18
- Intro of Peter Slack 1:47
- How did OSN start? 2:35
- When did you get into meetings and where do you see meetings going? 5:40
- Where do you see media going? 7:46
- How did you end up running the Hawaiian Eye Meeting? 10:53
- Intro of Greg Kunst 13:59s
- What will be the biggest challenges introducing a new paradigm for a traditionally surgical disease? 14:52
- What can you tell us about Aurion’s plans for cell therapy in other front and back of the eye disease, in addition to endothelial cell disease? 17:04
- What should I be telling my patients who have future need for endothelial keratoplasty? 19:17
- What is the status of Aurion in Japan? Is the competition on the horizon? 22:13
- Intro of Rich Small 25:53
- Why are you excited about the Encapsulated Cell Therapy Platform? 27:12
- Why MacTel? 31:52
- What is the status of the Neurotech BLA? 32:26
- Give us a good Jim Mazzo story 34:38
- Intro of Uday Devgan, MD, FACS, FRCS(Glasg) 37:05
- Tell us about how you got started producing one video per day 38:10
- Tell us a story about a doctor from far away who is influenced by your teaching 40:38
- If you could change one thing in residency training today, what would it be? 41:59
- Preview of episode 20 43:51
- Feedback, questions and guest suggestions at eyeluminaries@healio.com 44:04
Uday Devgan, MD, FACS, FRCS(Glasg), is Healio|OSN section editor for Ocular Surgery News. He is in private practice, specializing in cataract and refractive surgery, at Devgan Eye Surgery in Los Angeles and a full partner at Specialty Surgical Center in Beverly Hills, California. He has previously served as full clinical Professor of Ophthalmology at the Jules Stein Eye Institute at the UCLA School of Medicine as well as Chief of Ophthalmology at Olive View-UCLA Medical Center and has been actively involved in resident surgical teaching for over two decades. He owns and operates CataractCoach.com.
John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California.
Greg Kunst is president, chief executive officer and board member at Aurion Biotech. He is focused in areas such as R&D, clinical development, corporate development, strategy, marketing, commercial, business development, market access and medical affairs with extensive knowledge of global health care markets (North America, Latin America, Europe, Asia), global commercialization and market development, upstream and downstream marketing, market access, and medical affairs for medical device, drug delivery systems, diagnostic systems, biotechnology, cell therapies, gene therapies, biologics, and pharmaceutical products.
Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA.
Peter N. Slack is president and chief executive officer of The Wyanoke Group. Peter is past-Chairman and a current member of the Board of Trustees for the Center for Family Services, a nonprofit human services agency. Other professional titles and memberships have included Board of Directors of the International Association of Association Management Companies and Board of Directors of the American Medical Publishers Association. In addition, Peter is President of the Broadway Theatre of Pitman in Pitman, NJ. Disclosure: The Wyanoke Group is the holding company for Healio, the producer of the Eyeluminaries podcast.
Rich Small is chief executive officer and member of the board of directors for Neurotech. He originally joined Neurotech in July 2007 as the company’s chief financial officer. He has in excess of 30 years of both private and public life sciences experience and more than 40 years of overall financial and operational management. Previously Rich served as Senior Vice President and Chief Financial Officer of Point Therapeutics, a publicly traded biotechnology company focused in developing treatments for various cancers.
We’d love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian.
Collapse
Read more about
Click Here to Manage Email Alerts
